epidermolysis bullosa

(redirected from Dystrophic Epidermolysis Bullosa)
Also found in: Medical, Encyclopedia.

epidermolysis bullosa

(ˌɛpɪdɜːˈmɒlɪsɪs bʊˈləʊzə)
n
1. (Pathology) a group of genetic disorders causing blistering of the skin and mucous membranes. In simple cases the blistering is induced by injury, but in serious cases it occurs spontaneously
2. (Medicine) a group of genetic disorders causing blistering of the skin and mucous membranes. In simple cases the blistering is induced by injury, but in serious cases it occurs spontaneously

epidermolysis bullosa

(EB) An inherited disorder in which the skin is faulty or inadequate. The layers of the skin separate easily if damaged or touched, and then blister. Sufferers are prone to infection.
References in periodicals archive ?
Maxim Group analyst Jason McCarthy recently downgraded Abeona from Buy to Neutral, citing the additional capital the company might need, and keeping in mind the funding needs for initiating a Phase 3 study of EB-101 in recessive dystrophic epidermolysis bullosa and the company's cash burn rate.
Our team remains highly focused on our lead programs, including the start of our VIITAL Phase 3 clinical trial in recessive dystrophic epidermolysis bullosa, continued enrollment in the MPS III programs, and preparations to start the clinical trial in CLN1 disease.'
Recessive Dystrophic Epidermolysis Bullosa or RDEB is an incurable condition caused by a lack of collagen protein in the skin.
M2 EQUITYBITES-May 1, 2019-Phoenix Tissue Repair passes US FDA fast track designation for PTR-01to treat dystrophic epidermolysis bullosa
M2 PHARMA-May 1, 2019-Phoenix Tissue Repair passes US FDA fast track designation for PTR-01to treat dystrophic epidermolysis bullosa
Fibrocell Science Inc., a cell and gene therapy company focused on cell-based therapies for skin and connective tissue diseases, announced the completion of a collaboration agreement with Parsippany-based Castle Creek Pharmaceuticals to develop and commercialize Fibrocell's lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disorder diagnosed at infancy with no cure or treatment approved by the U.S.
Fibrocell Science (FCSC) announced the completion of a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell's lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa. Under the terms of the collaboration agreement, Castle Creek Pharmaceuticals will receive an exclusive license to commercialize FCX-007 in the United States.
Induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Ann Transl Med.
ProQR is developing its RNA platform technology in areas of ophthalmology, cystic fibrosis and dystrophic epidermolysis bullosa. Through a collaboration with Amylon Therapeutics, the platform is also being developed for CNS indications including HCHWA-D.
James has been campaigning to help the national charity DEBRA (the Dystrophic Epidermolysis Bullosa Research Association) raise awareness and money, in the hope that a cure can be found.
Full browser ?